Fosun Pharma's Subsidiary Henlius Enters Licensing Agreement with Eisai for Cancer Treatment

Stock News02-05 16:57

Fosun Pharma's controlled subsidiary Henlius has entered into a licensing agreement with Eisai, granting the latter exclusive rights to develop, manufacture, and commercialize the innovative anti-PD-1 monoclonal antibody serplulimab injection in Japan for oncology indications. Under the agreement, Eisai will make non-refundable payments to Henlius totaling up to $155.01 million, including an initial payment of $75 million upon signing and regulatory milestone payments of up to $80.01 million tied to approval progress in Japan. Additionally, Eisai will pay sales milestone amounts of up to $233.33 million based on annual net sales performance of the licensed product in the territory. The collaboration is expected to enhance the global market presence and international recognition of Fosun Pharma's proprietary pharmaceutical products.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment